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Abstract
Objective: Hereditary spastic paraplegias (HSPs) are among the most geneti-
cally diverse inherited neurological disorders, with over 70 disease loci identi-
fied (SPG1-71) to date. SPG15 and SPG11 are clinically similar, autosomal
recessive disorders characterized by progressive spastic paraplegia along with
thin corpus callosum, white matter abnormalities, cognitive impairment, and
ophthalmologic abnormalities. Furthermore, both have been linked to early-
onset parkinsonism. Methods: We describe two new cases of SPG15 and inves-
tigate cellular changes in SPG15 and SPG11 patient-derived fibroblasts, seeking
to identify shared pathogenic themes. Cells were evaluated for any abnormali-
ties in cell division, DNA repair, endoplasmic reticulum, endosomes, and lyso-
somes. Results: Fibroblasts prepared from patients with SPG15 have selective
enlargement of LAMP1-positive structures, and they consistently exhibited
abnormal lysosomal storage by electron microscopy. A similar enlargement of
LAMP1-positive structures was also observed in cells from multiple SPG11
patients, though prominent abnormal lysosomal storage was not evident. The
stabilities of the SPG15 protein spastizin/ZFYVE26 and the SPG11 protein spa-
tacsin were interdependent. Interpretation: Emerging studies implicating these
two proteins in interactions with the late endosomal/lysosomal adaptor protein
complex AP-5 are consistent with shared abnormalities in lysosomes, support-
ing a converging mechanism for these two disorders. Recent work with
Zfyve26/ mice revealed a similar phenotype to human SPG15, and cells in
these mice had endolysosomal abnormalities. SPG15 and SPG11 are particularly
notable among HSPs because they can also present with juvenile parkinsonism,
and this lysosomal trafficking or storage defect may be relevant for other forms
of parkinsonism associated with lysosomal dysfunction.
Introduction
Hereditary spastic paraplegias (HSPs) are a heteroge-
neous group of inherited neurological disorders with the
cardinal feature of a length-dependent axonopathy of
corticospinal motor neurons.1 Historically, they have
been classified as either pure or complex based on the
absence or presence, respectively, of associated signs and
symptoms. They are now mainly classified by their
mapped genetic loci, SPG1 to SPG71. To date, well over
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40 genes have been identified, encompassing autosomal
dominant, autosomal recessive, X-linked, and maternal
inheritances, with de novo mutations also described.1–5
Despite this broad genetic heterogeneity, several com-
mon cellular mechanistic themes have emerged. Notably,
alterations in the formation and function of the endo-
plasmic reticulum network in cells have been associated
with the most common pure HSPs with autosomal
dominant inheritance,2 while numerous complex HSPs
with autosomal recessive inheritance have been linked to
defects in endosomal dynamics.1–5
A subset of complex forms of HSPs can be distin-
guished by prominent thinning of the corpus callosum
(TCC). These forms comprise almost one third of
recessive complex HSP cases,2,6 with ~70% of these
resulting from mutations in either SPG15/ZFYVE26
(MIM# 270700) or SPG11/KIAA1840 (MIM# 604360).
Both disorders can also present with retinal or lenticu-
lar abnormalities, and they are often associated with
cognitive impairment as well as prominent juvenile par-
kinsonism that can be responsive to dopaminergic ther-
apy.7–9 Cerebellar findings including ataxia and
impaired extraocular muscle movements are also com-
monly observed. Most cases of SPG15 and SPG11 have
mutations that are predicted to lead to loss-of-function
or elimination of the spastizin or spatacsin proteins,
respectively. Both spastizin and spatacsin are large pro-
teins, ~270–280 kDa each, present in a common protein
complex. They have predicted secondary structures con-
taining a-solenoids reminiscent of those in clathrin
heavy chain and COP-I subunits. Spatacsin also has an
N-terminal, b-propeller-like domain, and spastizin har-
bors a zinc-binding FYVE (present in Fab1, YOTB,
Vac1, and EEA1) domain. Spastizin has been localized
to different and often disparate intracellular locations in
various studies.9–15 Similarly, proposed functions vary
broadly and include cytokinesis, DNA repair, late en-
dosomal/lysosomal trafficking, and autophagy.10–16 Func-
tions of spastazin and spatacsin relevant for HSP
pathogenesis remain unclear.
Recently, a mouse model of SPG15, Zfyve26/, has
been generated that recapitulates many features of the
human disease.17 These mice develop late-onset spastic
paraparesis associated with cerebellar ataxia, resulting
from axonal degeneration and progressive loss of both
cortical upper motor neurons and cerebellar Purkinje
cells. Interestingly, Zfyve26/ Purkinje cells possess an
increased number of enlarged Lamp1-positive organelles,
some of which harbor storage material. Electron micros-
copy (EM) revealed these structures to be large mem-
brane-enclosed deposits, with some reminiscent of
fingerprint bodies. Thus, loss of spastizin alters the endo-
lysosomal system in vivo.17
We briefly describe two siblings with compound het-
erozygous mutations of SPG15 who possess the cardinal
findings of SPG15. Investigations of cells derived from
these individuals indicate that SPG15 cells divide nor-
mally and exhibit normal DNA repair. Furthermore, these
SPG15 cells have markedly decreased levels of both spasti-
zin and spatacsin. Similarly, cells derived from SPG11
patients have diminished levels of both proteins. Both
types of patient cells exhibit enlarged LAMP1-positive
structures, while SPG15 cells also exhibit aberrant multila-
mellar storage material as seen in the Zfyve26/
mice.17,18
Case Report
On initial presentation to the NINDS Neurogenetics
Branch, subjects II-2 and II-3 were undiagnosed siblings,
each with a >6-year history of spastic paraparesis
(Fig. 1A). Subject II-2 was a 24-year-old man uncoordi-
nated for most of his life, and who over the last several
years had developed a moderate, mixed spastic and cer-
ebellar dysarthria. He was a below average student, but
graduated high school and completed some college. Sub-
ject II-3 was a 26-year-old woman who earlier in her
life was athletic. She developed progressive balance diffi-
culties and falls in her late teens, initially affecting the
right side more than the left. Over the last several years,
she had also developed a fine action tremor, dysarthria
and cognitive decline, and she was no longer able to
work.
On examination, II-2 had markedly increased spasticity
in the lower extremities, but normal tone in the upper
extremities. Muscle bulk was normal, but mild weakness
was noted in ankle dorsiflexors and extensor hallucis lon-
gus bilaterally. Vibratory sensation was minimally
decreased at the great toes. Deep tendon reflexes were
moderately increased in the upper extremities, but mark-
edly increased in the lower extremities, with sustained
ankle clonus. Plantar responses were extensor. Gait was
severely spastic and mildly ataxic. Although he had no
obvious rigidity, subsequent initiation of levodopa ther-
apy subjectively improved his gait.
Patient II-3 was able to ambulate only short distances
with a walker. Her motor examination was notable for
markedly increased lower extremity spasticity associated
with mildly increased upper extremity tone. She had
moderate weakness of ankle dorsiflexors, extensor hallucis
longus, and hip flexors; hamstrings were only mildly
weak. She had a mild action tremor, slowed rapid alter-
nating movements, and mild dysmetria bilaterally. Vibra-
tory sensation was minimally decreased at the great toes.
Deep tendon reflexes were markedly increased in the
lower extremities, with sustained ankle clonus. Plantar
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responses were extensor. Levodopa therapy subjectively
improved both tremor and gait.
Neither the parents (I-1 and I-2) nor a sister (II-1) had
neurological complaints. Neurological examination of the
parents and sister revealed no abnormalities.
Cranial magnetic resonance imaging (MRI) of both
affected siblings revealed marked TCC (Fig. 1B). This
thinning was particularly notable in anterior/middle por-
tions, while the splenium appeared relatively spared. Axial
fluid attenuation inversion recovery images emphasized
an area of abnormal signal notable in the region of the
forceps minor of the corpus callosum, the “ears of the
lynx” sign described in many SPG15 and SPG11 patients
(Fig. 1B).6,19 Ophthalmologic examination in the affected
siblings was notable for small yellowish flecks, some with
pigmentary changes, in the macular region of the retina
with sparing of the fovea, as seen in other SPG15 and
SPG11 patients.20,21 These flecks were less apparent in II-
3, but autofluorescence images revealed more retinal
involvement. Furthermore, subject II-3 had patchy lentic-
ular opacities (Fig. 1C and D). Both affected siblings had
normal visual acuity.
Genetic testing of II-3 revealed no SPG11 mutations.
However, commercial testing of SPG15 (Centogene,
Rostock, Germany) revealed compound heterozygous
mutations in both affected subjects. The paternally
derived variant was a splice-site mutation in the acceptor
site of intron 14 (c.2554-1 G>A), resulting in the skipping
of exon 15. The maternally derived variant was a non-
sense mutation in exon 19 causing truncation of the pro-
tein (c.3417_3418insTA; p.Lys1140X). The unaffected
sibling (II-1) had no SPG15 abnormalities. These studies
combined with the characteristic clinical and neuroimag-
ing findings established a diagnosis of SPG15 in II-2 and
II-3.
Subjects/Materials and Methods
Study oversight
Subjects were enrolled in protocols approved by the
National Institute of Neurological Disorders and Stroke
and National Human Genome Research Institute Institu-
tional Review Boards. All subjects provided written
Figure 1. Clinical and imaging features of SPG15. (A) Pedigree of SPG15 family. Square: male; circle: female; solid symbol: affected individual.
(B) T1-weighted sagittal MRI images (left) show enlarged ventricles and TCC in the SPG15 affected siblings. Axial fluid attenuation inversion
recovery images (right) show increased signal particularly in the region of the forceps minor, just anterior to the rostral-most portion of the lateral
ventricles. (C) Small, white, peripheral cortical lens opacities are evident in SPG15 patient II-3 (right eye shown). (D) Yellowish flecks are notable in
the retinas of SPG15 patients, particularly in II-2; these were more apparent by autofluorescence in II-3 (right panel).
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informed consent and were evaluated at the NIH Clinical
Center. The SPG15 family consisted of two affected sib-
lings plus both parents and an unaffected sister (Fig. 1A).
SPG11 patients from two different families were previ-
ously reported.9
Cell culture and immunoblotting
Skin punch biopsies were obtained and primary fibroblast
cell lines were established using standard procedures.
Immunoblotting was performed as described previously22
using primary antibodies against spastizin (ProSci, Poway,
CA), spatacsin (Proteintech, Chicago, IL, 16555-1-AP),
PLC1c1 (Cell Signaling Technology, Danvers, MA), and
b-tubulin (Sigma-Aldrich, St. Louis, MO).
Quantitative RT-PCR
Total RNA was extracted from fibroblast cells with TRIzol
reagent (Invitrogen, Grand Island, NY). Reverse transcrip-
tion of total RNA with Oligo(dT)20 (Invitrogen) was per-
formed using ThermoScript RT-PCR System (Invitrogen).
cDNA was amplified with specific primer sets (Table S1) in
a Bio-Rad C1000 thermocycler (Hercules, CA). Quantita-
tive real-time polymerase chain reaction (PCR) was carried
out using an Applied Biosystems 7900HT System (SYBR
green PCR Master Mix; Grand Island, NY). The following
cycling program was applied: 10 min at 95°C, 40 cycles of
15 sec at 95°C, 30 sec at 60°C, and 1 min at 72°C. Data
were normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and actin levels using the comparative
threshold cycle method.
Confocal immunofluorescence microscopy
Confocal microscopy was performed as described previ-
ously22 using the following primary antibodies: b-tubulin
(IgG1, clone D66; Sigma-Aldrich), Ki67 (ab15580; Abcam,
Cambridge, MA), LAMP-1 (Abcam), SNX1 (BD Bioscienc-
es, San Jose, CA), EEA1 (BD Biosciences), FAM21 (EMD
Millipore, Billerica, MA), calreticulin (Abcam), and LC3
(L8918; Sigma-Aldrich). Cells were counterstained with
40,6-diamidino-2-phenylindole (DAPI; 0.1 mg/mL) where
indicated. For labeling of acidic organelles, LysoSensor
Green DND-189 (1 lmol/L) was added to cells in growth
medium and incubated at 37°C for 30 min before imaging.
A Zeiss LSM710 confocal microscope (Thornwood, NY)
with a 639 1.4 NA Plan-Apochromatic oil differential
interference contrast objective was used, and image acqui-
sition was performed using LSM710 version 3.2SP2 soft-
Figure 2. The SPG15 protein spastizin is absent in SPG15 patient fibroblasts. (A–C) Quantitative PCR analysis of spastizin mRNA using primers
targeting both 50 (A) and 30 (B) ends. Actin and GADPH were used as standards. Graphs show mean  SD. Relative total mRNA levels are shown
in (C). Similar results were obtained in at least two additional independent experiments. NA, negative control. (D) Immunoblot analysis of spastizin
in HeLa cells transfected with control or spastizin-specific siRNAs as well as cultured fibroblasts from the indicated subjects. An asterisk (*)
identifies a cross-reacting protein. PLCc1 levels were monitored as a control for protein loading. Migrations of protein standards (in kDa) are at
the left.
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ware. Images were analyzed with ImageJ (NIH, Bethesda,
MD) and edited using Adobe Photoshop 7.0 and Illustrator
CS5 software.
Transmission EM
Transmission EM was performed on primary fibroblast
cultures as described previously.22 Immunogold-EM was
performed as described in Chang et al.23
siRNA transfection
HeLa cell transfections were performed using Lipofectam-
ine RNAi MAX (Invitrogen). The ON-TARGET plus siR-
NA pool against SPG15 was obtained from Dharmacon
(Lafayette, CO), and control siRNAs were from Abcam.
DQ-BSA dequenching assay
The DQ-BSA dequenching assay was performed as
described previously.24 Wild-type and patient fibroblast
cells were seeded on 24-well plates. The next day, media
were changed 2 h before DQ-BSA-red (10 lg/mL, Invi-
trogen) treatment for 18 h. Cells were washed twice with
phosphate-buffered saline, and red fluorescent signals
were captured by confocal microscopy using the same
exposure time for all experimental groups.
Results
Loss of spastizin protein in SPG15
fibroblasts
Fibroblast cell lines from family members were used to
evaluate the cellular pathogenesis of SPG15. Comparative
real-time quantitative PCR revealed that the parents’ cell
lines (I-1 and I-2) had reduced spastizin mRNA com-
pared with the unaffected sister (II-1), while the affected
siblings (II-2 and II-3) had nearly undetectable levels of
spastizin mRNA (Fig. 2A–C). We next examined spastizin
protein levels in fibroblasts from the three siblings. A
spastizin-specific band was initially identified in HeLa
cells using a spastizin-specific siRNA to selectively deplete
the spastizin band located in a protein doublet near its
predicted size (~280 kDa). Consistent with the quantita-
tive mRNA data, this spastizin-specific band was present
in the unaffected sibling (II-1) but absent in both affected
subjects (Fig. 2D).
Lack of spastizin does not impair cell
division or DNA repair in fibroblasts
Since spastizin has been implicated in cytokinesis through
a KIF13A-mediated recruitment of spastizin/FYVE-CENT
to the midbody,25 we investigated cytokinesis in fibro-
blasts from this family. No differences in percentages of
mitotic cells or cells with midbodies were seen (Fig. S1).
Furthermore, cell proliferation assessed by Ki67 staining
was similar in cells from affected and unaffected family
members (Fig. S2). Fluorescence-activated cell sorting
studies analyzing DNA content in BrdU-labeled cells also
did not differ among the cell lines (Fig. S3). Thus, we
have no evidence that chronic lack of spastizin impairs
cell division.
Another published study reported a role for the SPG48
protein KIAA0415 in DNA repair.10 Since KIAA0415 co-
precipitates with spastizin and spatacsin,10,16 we investi-
gated the induction of, and recovery from, DNA damage
induced in fibroblasts with H2O2, using an alkaline comet
assay.26 We observed no differences among the cell lines,
Figure 3. SPG15 fibroblast cells exhibit prominently enlarged lysosomes. (A) Immunostaining of LAMP1 and SNX1 (both in red) proteins in the
indicated fibroblast cell lines. Boxed areas are enlarged in the insets. Scale bars: 20 lm. (B) Quantification of lysosome circumference from subject-
derived cells, mean  SEM (n = 3 independent experiments, each evaluating at least 250 lysosomes). ***P < 0.001; unpaired Student’s t test.
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indicating that spastazin is dispensable for DNA repair
(Fig. S4).
SPG15 fibroblasts exhibit enlargement of
LAMP1-positive structures
Robinson, Hirst, and colleagues have recently presented
compelling in silico and biological support for
KIAA0415 functioning as the f subunit of a novel adap-
tor protein complex, AP-5, that appears to localize pre-
dominantly to late endosomes and lysosomes.11,12,16 We
examined markers for early endosomes by confocal
immunofluorescence microscopy, but saw no differences
in their appearance or localization among control and
SPG15 fibroblasts; the endoplasmic reticulum also
appeared normal (Fig. 3A and Fig. S5). Interestingly, we
observed prominent differences in LAMP1 (a lysosomal
marker) immunostaining in the SPG15 cells (Fig. 3B).
Subsequent studies with the pH-sensitive dye LysoSensor
Green indicated that most lysosomes in wild-type and
mutant cells had similar signal intensities, reflecting the
typical acidic pH, but SPG15 cells also harbored numer-
ous large, round subcellular structures devoid of fluores-
cence (Fig. 4A). Examination by EM revealed storage
material inclusions in SPG15 cells characteristic of
multilamellar “zebra bodies,”18 which are mainly com-
posed of membrane constituents that typically undergo
degradation in lysosomes (Fig. 4B). Immunogold-EM for
LAMP1 confirmed that these presumptive storage-filled
lysosomes or autolysosomes, representing the nonlabeled
structures seen upon LysoSensor staining, are LAMP1-
positive (Fig. 4C).
Figure 5. Both spastizin and spatacsin proteins are depleted from
SPG15- and SPG11-patient cell lines. Cell extracts prepared from
SPG15 (II-2) and SPG11 patient cell lines were immunoblotted (IB) as
shown. PLCc1 and b-tubulin levels were monitored as controls for
protein loading. Asterisks (*) identify cross-reacting proteins.
Migrations of protein standards (in kDa) are at the left.
Figure 4. SPG15 fibroblasts harbor numerous multilamellar zebra bodies. (A) Confocal microscopy analysis of the indicated fibroblast lines
stained with LysoSensor Green. Boxed areas in the left panels are enlarged at the right. Scale bar: 10 lm. (B) EM reveals numerous membranous
multilamellar zebra bodies throughout the cytoplasm of fibroblasts cultured from subject II-3 (shown) and II-2 (not shown), who have SPG15, but
not in cells from an unaffected sister (I-1). Scale bars: 500 nm. (C) Immunogold-EM shows LAMP1 immunoreactivity rimming storage-filled
structures. These structures appear different than in B because here cells were permeabilized with the detergent saponin, altering the
membranes, and the OsO4 concentration was much lower, decreasing membrane contrast. Scale bars: 500 nm.
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Spastazin and spatacsin stability are
codependent and SPG11 cells also exhibit
enlarged LAMP1-positive structures
A remarkable feature of SPG15 is its virtual clinical iden-
tity to SPG11.2 Spastizin and spatacsin proteins also co-
precipitate, indicating a possible common cellular
pathogenesis.10,14,16 We evaluated the presence of both
proteins in SPG15 fibroblasts, as well as in fibroblasts
from three different, previously reported SPG11 patients
from two different families.9 The SPG11 patients each
had onset of symptoms before age 20, with spastic para-
paresis, cognitive decline, levodopa-responsive parkinson-
ism, and the “ears of the lynx” brain MRI sign.9
Interestingly, SPG15 fibroblasts had almost no identifiable
spatacsin, while SPG11 fibroblasts had markedly decreased
levels of spastizin (Fig. 5). SPG11 fibroblasts also exhib-
ited an increase in lysosomal size as assessed by LAMP1
staining (Fig. 6A–C), whereas early endosomes and the
endosome-associated WASH complex were unchanged
(Fig. S6). Thus, enlarged LAMP1-positive structures were
visualized in all five SPG15 and SPG11 cell lines exam-
ined. Together, these data suggest a codependence of
these proteins. Unexpectedly, when evaluated by EM none
of the SPG11 fibroblast lines possessed the prominent
multilamellar structures seen in the SPG15 cells (Fig. 6D
Figure 6. Fibroblasts from SPG11 patients also exhibit enlarged LAMP1-positive structures. (A and B) Confocal microscopy analysis of the
fibroblast cell lines stained with LAMP1 antibodies: (A) control and SPG15 fibroblasts; (B) SPG11 fibroblasts. Insets in the left panels are enlarged
at the right. Nuclei are stained with DAPI. (C) Quantification of lysosome circumference from subject-derived cells, mean  SEM (n = 3
independent experiments, each evaluating at least 250 lysosomes). (D) EM of SPG11 fibroblasts. Scale bar: 500 nm. (E–G) LC3-positive
autophagosomes were counted in the indicated fibroblast lines (mean  SD, n = 3 independent experiments, each evaluating at least 200 cells).
DAPI staining identifies the nucleus. Scale bar: 10 lm. ***P < 0.001; **P < 0.01; *P < 0.05; paired Student’s t test.
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and data not shown), despite the fact that the lysosomes
appeared similarly enlarged. Of note, the large, LysoSen-
sor nonlabeled structures in SPG15 cells were also absent
in SPG11 cells (data not shown). Autophagy is the pre-
dominant lysosome-mediated degradative process in cells
and, concordant with the finding of autophagosome accu-
mulation in SPG15 patient cells by Vantaggiato et al.,15
we observed an increase in autophagosome number
(assessed using LC3 staining) in all SPG15 and SPG11
fibroblast lines tested (Fig. 6E–G).
Multilamellar zebra bodies are often seen in cells
derived from patients with lysosomal storage disorders
due to mutations in lysosomal acid hydrolases.18 Given
the presence of these structures in the SPG15 cells
and the LAMP1 enlargements in SPG15 and SPG11 cells,
we investigated lysosomal enzyme activities in cellulo with
fluorescent DQ-BSA. In this assay, the digestion of
fluorescent DQ-BSA by lysosomes results in dequenching,
and thus an increase in fluorescence. Lysosomal enzyme
activities appeared normal across all SPG15 and SPG11
cell lines tested, though there was a nonsignificant trend
toward slightly decreased activity (Fig. 7).
Discussion
We have identified a new family with two siblings harbor-
ing compound heterozygous mutations in the SPG15
gene, resulting in complicated HSP. Their phenotypes
were consistent with previous descriptions of SPG15 and
included TCC, white matter signal abnormalities, ophthal-
mologic changes, mild ataxia, parkinsonism, and progres-
sive cognitive deficits. These cases further emphasize the
importance of considering this diagnosis in nonconsan-
guineous populations and families.
Figure 7. Lysosomes of SPG11 and SPG15 patient cells appear enzymatically functional. Control (II-1) and patient fibroblast cells labeled by DQ-
BSA-red were imaged. The intensities of manually determined areas for each single cell were measured using ImageJ measurement tools. All cell
lines were analyzed in duplicate for DQ-BSA treatment. The graph shows mean  SEM (n = 30). AU, arbitrary unit. Scale bar: 100 lm.
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SPG15 appears almost clinically identical to another
complicated spastic paraplegia, SPG11. In fact, both can
present with juvenile parkinsonism that responds to
dopaminergic medications.9 Although our affected sib-
lings had only mild parkinsonism, they did have a subjec-
tive improvement on dopaminergic therapy. Since a
majority of complicated HSP cases with TCC are SPG15
or SPG11, further understanding the pathogenesis of these
disorders is important.
Previously, a number of different cellular pathogenic
mechanisms have been suggested for SPG15 and SPG11:
defective DNA repair, cell division abnormalities, endolys-
osomal dysfunction, and impaired autophagy. For SPG15,
in particular, our data do not support defects in either
DNA repair or cytokinesis playing a significant role in
pathogenesis, since cell lines from two patients showed no
obvious effects on these processes. Our results showing
selective lysosomal enlargement could be consistent with
a role for defective lysosomal fusion with autophagosomes
in disease pathogenesis, as suggested by Vantaggiato
et al.15 An alternative hypothesis could be that this
enlargement is related to an intrinsic endolysosomal traf-
ficking defect; the recently described AP-5 adaptor protein
complex (mutated in SPG48) binds to both spastizin and
spatacsin, while also colocalizing with the lysosomal
protein LAMP1.11,12,16 In fact, data from the Zfyve26/
mouse model further support a role for the endolysoso-
mal system in SPG15 pathogenesis.17 Our SPG15 subjects’
ophthalmologic abnormalities included retinal lesions and
lens opacities, both likely reflecting the accumulation of
storage material. Neurodegeneration and white matter
changes leading to cognitive decline and spasticity in
SPG15 are often seen in other lysosomal disorders as
well.27
SPG11 is clinically very similar to SPG15, and knock
down of the zebrafish SPG15 and SPG11 orthologs
zspg15 and zspg11, respectively, leads to a common
phenotype of severely compromised spinal motor axon
outgrowth,14 consistent with a converging pathogenic
mechanism. Indeed, in addition to the loss of spatacsin,
SPG11 patient fibroblasts also had reduced expression
of spastizin along with similarly enlarged lysosomes.
Unexpectedly, EM evaluations of SPG11 fibroblasts
from several patients did not reveal the multilamellar
storage material seen in SPG15 patient fibroblasts. The
difference between the SPG11 and SPG15 fibroblasts
could be due to several factors including genetic back-
ground, the fact that some residual spastizin was pres-
ent, or that there is some functional redundancy for
spatacsin in these cells. Further studies with induced
pluripotent stem cell-derived neurons may provide fur-
ther explanation for these differences. A comprehensive
study of SPG11 and SPG15 patients is also warranted,
with an emphasis on the evaluation of cell lines and
postmortem tissues.
Finally, SPG15 and SPG11 can present with juvenile
parkinsonism, and lysosomal and autophagic dysfunction
are increasingly implicated in parkinsonism. For exam-
ple, Mazzuli et al. recently proposed a scheme for Par-
kinson’s disease whereby a-synuclein inhibits the
lysosomal activity of normal glucocerebrosidase.28,29 This
alteration mimics the lysosomal dysfunction associated
with glucocerebrosidase mutations in patients with Gau-
cher disease, another disorder linked with parkinson-
ism.30 Perhaps even more compelling, loss-of-function
mutations in the gene encoding the lysosomal membrane
protein ATP13A2 (PARK9) cause Kufor-Rakeb syn-
drome, an early-onset parkinsonism associated with
pyramidal degeneration and dementia. This overlaps
clinically with the SPG15/SPG11 phenotype, and
ATP13A2 fibroblasts exhibit impaired lysosomal degrada-
tive capacity.31 Finally, spatacsin is found in the periph-
eral portion of brainstem Lewy bodies in Parkinson’s
disease.32 These findings along with our data identifying
structural lysosomal abnormalities in SPG15 and SPG11
may extend the emerging links of lysosomal dysfunction
to parkinsonism.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. SPG15 patient-derived fibroblasts divide nor-
mally. (A) Merged images of actin (red) and DAPI (blue)
from fibroblasts in interphase (left) or during cytokinesis
(right). Insets show differential interference contrast
enlargements of the midbody region. Scale bars: 10 lm.
(B and C) Quantifications are shown for percentages of
fibroblasts interconnected by visible midbodies (B) as well
as for mitotic cells (C). Cells were maintained as
described in Subjects/Materials and Methods. Graphs
show mean  SEM (n = 3 independent trials; 100 cells
per experiment).
Figure S2. Cell proliferation appears normal in SPG15
patient fibroblasts. (A) Confocal microscopy analysis of
the indicated fibroblast cell lines stained with Ki67 and
b-tubulin antibodies, as indicated. Nuclei are stained with
DAPI, and merged images are to the right. Scale bars:
10 lm. (B) Quantification of cells accumulating Ki67 in
subject-derived fibroblasts. Mean  SEM is shown (n = 3
independent experiments, with at least 200 cells per
experiment). There are no significant differences.
Figure S3. Cell cycle analysis by fluorescence-activated
cell sorting (FACS) shows no significant changes between
SPG15 subjects and unaffected family members. Methods:
BrdU-labeled cells were identified using anti-BrdU-FITC
antibody (BD Biosciences) and all cells were counter-
stained with propidium iodide (PI; Invitrogen) to mea-
sure their total DNA content using a standard flow
cytometry labeling protocol. Cell samples were assayed
using the FACSVantage SE flow cytometer (BD Bioscienc-
es) equipped with an argon-ion laser tuned to 488 nm
and the resulting FITC and PI fluorescence emissions
from each cell were collected using bandpass filters set at
530  30 nm and 613  20 nm, respectively. CellQuest
acquisition and analysis software (BD Biosciences) was
used to acquire and quantify the percentages of cells at
specific stages of the cell cycle and apoptosis using empir-
ical gates set on differential distributions of anti-BrdU-
FITC and PI-labeling intensities under control conditions.
Apoptotic cells at different stages of the cell cycle were
identified using differential labeling with anti-BrdU-FITC
and their hypodiploid or hypotetraploid total DNA con-
tent, with the latter parameter indicating a loss of normal
DNA, which occurs during late stages of apoptosis. For
example, cells undergoing apoptosis from G0/G1 stage of
the cell cycle are BrdU and exhibit hypodiploid DNA
content (R4 region in the BrdU vs. PI dot density plot),
whereas cells undergoing apoptosis from S-phase of the
cell cycle have hypodiploid DNA content, but are BrdU+
(R5 region in the BrdU vs. PI dot density plot). In con-
trast, cells undergoing apoptosis from G2/M stage of the
cell cycle are BrdU and exhibit hypotetraploid DNA
content (R9 region in the BrdU vs. PI dot density plots).
Figure S4. Spastizin is not required for repair of oxidative
DNA damage in fibroblasts. (A) DNA damage and recov-
ery in subject-derived fibroblast cell lines were analyzed
using an alkaline comet assay. Scale bar: 40 lm. (B)
Quantification of the percentage of comets after hydrogen
peroxide treatment, with and without recovery as shown.
Mean  SEM is indicated (n = 3 independent experi-
ments, with 50 nuclei assessed per trial). Methods: DNA
was damaged by using hydrogen peroxide (12.25 mm,
45 min, room temperature) applied to cells in suspension.
Repair activities were measured after 30 or 60 min of
recovery. Cells were resuspended in low-melting tempera-
ture agarose and applied to slides coated with normal-
melting temperature agarose. After lysis, slides were
placed in a horizontal gel electrophoresis chamber and
covered with an alkaline buffer (5 mmol/L NaOH and
200 mmol/L EDTA; pH >13). Following a 20 min DNA
“unwinding” period, electrophoresis was performed
(20 V, 300 mA; distance between electrodes = 20 cm) for
25 min. Following neutralization with Tris base to pH
7.5, gels were stained with Vista Green DNA dye and
stored at 4°C until analysis.
Figure S5. Morphology of endoplasmic reticulum (ER)
and early endosomes appear normal in SPG15 patient
fibroblasts. Confocal microscopy analysis of the indicated
fibroblast cell lines stained with antibodies against the ER
marker calreticulin (red) and the early endosomal antigen
EEA1 (green). Merged images are to the right. Boxed
areas are enlarged in the insets. Scale bar: 10 lm.
Figure S6. Confocal analysis of control (II-1) and SPG11-
1 fibroblast lines immunostained for EEA1 and FAM21
endosomal markers (green) showed no significant differ-
ences. The nucleus is stained with DAPI. Scale bars:
10 lm.
Table S1. Primer sequences used for quantitative real-
time RT-PCR.
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